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Abstract 
Purpose: To obtain a higher yield of mouse leukemia inhibitory factor to maintain the proliferation 
potential of pluripotent stem cells at a low cost. 
Methods: A method was designed to produce recombinant mLIF protein (rmLIF) in Escherichia coli. 
Through analysis of rmLIF sequence, it was found that rare codons were interspersed. After mutation 
from rare codons to Escherichia coli (E. coli) preferred ones were selected, the mutated gene mLIFm 
was cloned into pET15b vector. The pET15b-mLIFm was then transformed into Rosetta-gami strain and 
induced with optimal conditions at 18 oC for 16 h. Mass spectrometry was carried out to identify the 
peptides.  
Results: After purification, the yield of the codon-optimized rmLIFm was 141 mg/L, compared with 110 
mg/L for the original rmLIF. Mass spectral analysis showed the presence of four major peptides each 
with an intensity > 10 % at m/z 1031.57, 1539.82, 1412.01 and 2229.10 in mLIFm, respectively. His-
tagged rmLIFm fusion protein displayed the potential to maintain the morphology of undifferentiated 
mouse embryonic stem cells (mESCs), which were positive for mESCs markers (Oct-4, Nanog, Sox-2, 
stage-specific embryonic antigen-1).  
Conclusion: The findings provide a means to produce mLIF in a short, useful, cost-effective and 
environmentally-friendly manner, and thus lays a foundation for further studies of mLIF. 
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Leukemia inhibitory factor (LIF) is a pleiotropic 
glycoprotein and a member of interleukin (IL)-6 
family. It induces mouse myeloid leukemic M1 
cells of terminal differentiation into macrophages 
[1]. A number of studies have shown that LIF is a 
multi-purpose cytokine with range of pleiotropic 
actions on different types of cells and tissues. 
Not only does it facilitate early embryogenesis 
and blastocyst implantation of mammals, it also 
induces the production of acute phase proteins 
by lipocyte formation and hepatocytes [2,3]. 
Furthermore, LIF is known as a significant growth 
factor for maintaining embryonic stem cells and 
inducing pluripotent stem cells in a pluripotent 
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status [4]. LIF is routinely added to the medium 
of pluripotent stem cells and without LIF leads to 
a fast differentiation of pluripotent stem cells. 
Therefore, it is extensively employed in the 
culture of pluripotent stem cells [5]. The cells play 
a primary role in cell therapies and tissue 
replacement therapies [6,7]. Recently, rhLIF was 
successfully produced and purified by several 
groups using different kinds of expression 
systems such as E. coli [8-10], yeast cells and 
even in rice [11]. An issue arising from this 
process is the soaring cost of LIF and other 
cytokines in pluripotent stem cells research. 
Numerous studies have suggested that the cost 
of commercially produced LIF accounts for about 
90 % pluripotent stem cells culture medium [8]. It 
is urgent to obtain various forms of LIF in high 
quantities and at a low cost and biological active.  
 
E. coli is a commonly used host for expression of 
heterologous protein, but has a marked 
preference for certain codons. Differences in 
preference for codons between prokaryotes and 
eukaryotes can seriously affect protein 
production in E. coli. Rare codons exist in cloned 
genes that can affect many aspects such as 
protein expression and mRNA. Moreover, rare 
codons correlate with a small number of 
homologous tRNA in host cells. 
 
In the present study, a cDNA encoding LIF from 
mice was cloned and sequenced. Subsequently, 
we developed an effective method to produce 
soluble rmLIFm in E. coli after mutation from rare 
codons to E. coli preferred ones was performed. 
This method allowed rapid and effective 







T4 DNA ligase, Sma I and SYBR were purchased 
from Takara (Tokyo, Japan). FBS, L-glutamine 
and β-mercaptoethanol, minimum essential 
amino acids were purchased from Gibco 
(Karlsruhe, Germany). Goat anti-mouse IgG 
Goat anti-mouse IgGs (containing horseradish 
peroxidase label), anti-Oct-4 and anti-Nanog 
were purchased from Santa Cruz Biotechnology 
(Santa Cruz, USA). E. coli cells were purchased 
from Novagen (New York, USA). The other 
reagents were commercially available. 
 
Analysis of codons and amino acid 
sequences of mLIF 
 
BLASTP program was used to search for 
homologs of mouse LIF from other species. 
Different LIF sequences were compared using 
the Clustal X program. The rare codons of mLIF 
were analyzed. In addition, the relationship 
between mouse LIF and other previously 
described mammal LIF were showed by a 
phylogenetic tree, which was constructed using 
the program Phylip-3.69. 
 
Cloning the coding sequence of mLIF 
into expression vector 
 
PCR was used to amplify the coding region of 
the mouse leukemia inhibitory factor with the 
cDNA of mouse embryonic fibroblast (MEF) cells 
as a template. The forward primers (5′-
GTTCTGCACTGGAAACACG-3′) and the 
reverse (5′-CTAGAAGGCCTGGACCACC-3′) 
were designed based on the mRNA sequence of 
mouse leukemia inhibitory factor (NM_008501).  
 
The mLIFm sequence which mutated from rare 
codons to E. coli preferred ones, was directly 
synthesized by Invitrogen Company. The mLIF 
and mLIFm were ligated into the modified 
expression vector pET15b (Sma I) using T4 DNA 
ligase.  
 
Expression, purification and western blot 
analysis of rmLIFm 
 
E.coli Rosetta-gami cells harboring expression 
plasmids were incubated at 37 ℃ until OD600 
reached 0.6. IPTG was then added at a 
concentration of 0.5 mM. Subsequently, the 
culture was shaken constantly at 180 rpm for 16 
h at 18 ºC. The supernatant and precipitate were 
harvested by centrifugation (12,000 rpm for 10 
min). The supernatant was loaded onto a 5 mL 
Ni-NTA-His binding column equilibrated with 10 
mM imidazole (20 mM sodium phosphate pH7.4, 
500 mM NaCl). The protein bound matrix was 
washed with 20 mM imidazole (20 mM sodium 
phosphate pH 7.4, 500 mM NaCl). The protein 
was eluted with 250 mM imidazole (20 mM 
sodium phosphate pH 7.4, 500 mM NaCl). The 
concentrated sample was tested by BCA assay. 
 
Protein sample of the rmLIFm was separated on 
SDS-PAGE, followed by transfer onto a PVDF 
membrane. The PVDF membrane was blocked 
for 1.5 h at 25 ºC. It was then incubated with 
mouse anti-His IgG antibody (1:1000) at room 
temperature. After 2 h, the PVDF membrane was 
incubated with goat anti-mouse IgG conjugated 
with horseradish peroxidase (1:1000) for 1.5 h at 
room temperature. After incubation, the specific 
protein bands were developed using the 
diaminobenzidine (DAB) system. 
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Mass spectrometry analysis  
 
Sequencing grade modified trypsin (Promega, 
Madison, USA) was used to digest samples, 
matrix-assisted laser desorption/ionization time-
of-flight mass (MALDI-TOF-MS) was used to 
analyze samples by an ABI 4800 Plus MALDI 
TOF/TOF Analyzer (Invitrogen, Carlsbad, USA). 
IPI mouse database was used to analyze the 
result (V3.36) by GPS Explore software (V3.6, 
Invitrogen, Carlsbad, USA).  
 
Maintenance of mouse embryonic stem 
cells (MESCS) in culture 
 
We expanded the mouse embryonic stem cells 
line OG2 which was cultivated on mitomycin C 
handled mouse embryonic fibroblast (MEF) 
feeders. The culture medium was composed of 
DMEM (HyClone, Bonn, Germany) 
supplemented with 200 mM L-glutamine, 0.1 mM 
sodium bicarbonate, 0.1 mM β-mercaptoethanol, 
0.1 mM nonessential amino acids, 10 % FBS (all 
from Gibco, Karlsruhe, Germany) and 100 U/mL 
penicillin/streptomycin (Invitrogen, Camarillo, 
USA). The purified rmLIFm was added to the 
culture medium at a final concentration of 10 
ng/mL. 1000 U/mL of commercially available 
mouse leukemia inhibitory factor (Millipore, 
Billerica, USA) was used as positive control to 




RNA was extracted from 5 passages of mESCs 
with each mLIF supplementation. The expression 
of embryonic stem cell markers was investigated 
by Real-time PCR and primers were designed 
as: Oct-4 (FP-TAGGTGAGCCGTCTTTCCAC, 
RP- GCTTAGCCAGGTTCGAGGAT), Sox-2 (FP-
AGGGCTGGGAGAAAGAAGAG,RP-CCGCGAT 
TGTTGTGATTAGT), Nanog (FP- CTCAAGTCC 
TGAGGCTGACA, RP-TGAAACCTGTCCTTGAG 
TGC), GAPDH (FP-AACTTTGGCATTGTGGA 
AGGGCTCA, RP-TTGGCAGCACCAGTGGATG 
CAGGGA). For data normalization, the GAPDH 
was used as a reference gene to analyze the 
gene quantitatively. The reaction efficiency of 
primers was estimated by a standard curve. The 
2−ΔΔCt method was used to calculate the 




At the tenth passage of mESC culture (30 - 40 
days), cell morphology and the expression of 
ESC markers by immunofluorescence were used 
to ensure rmLIFm functionality. The 
undifferentiated state of mESC was determined 
by immunofluorescence staining with Oct-4 
(1:250; Santa Cruz Biotechnology, Santa Cruz, 
USA), Nanog (1:50; Santa Cruz Biotechnology, 
Santa Cruz, USA), Sox-2 (1:100; Stem Cell 
Technologies, Vancouver, Canada), and stage-
specific embryonic antigen-1 (1:50; Chemicon, 
Billerica, USA) 4 % paraformaldehyde was used 
to fixed the cells. After fixed for 10 min, the cells 
were washed with PBS 3 times, incubated with 
blocking buffer containing 0.1% Triton X-100 and 
10 % FBS in a humidity chamber at 37 ºC. After 
1 h, primary antibody was diluted in blocking 
buffer and applied for 2 h at 37 ºC, then washed 
three times. After incubation with secondary 
antibodies conjugated with TRITC (1:200, Sigma, 
Santa Cruz, USA) for 1h at 37 ˚C, they were 
washed twice in PBS, followed by incubation with 
PBS containing DAPI (10 μg/mL) for 5 min. DAPI 
stain solution was washed, fluorescence 
microscope was used to obtain pictures. 
 
Statistical analysis  
 
Data were expressed as mean ± standard 
deviation. The relative expression of Nanog, Oct-
4, and Sox-2 relative expressions were analyzed 
using Student’s t-test, only if p < 0.05 the 
differences were considered statistically 
significant. SPSS for Windows software (version 
13.0; SPSS Inc, Chicago, IL, USA) was used to 




Sequence of mLIF  
 
Bioinformatic analysis showed that the mLIF 
gene contains a 612-bp full open reading frame 
which encoded a 22.3 kDa protein with a pI of 
9.39. 
 
A signal peptide cleavage site was found 
between positions 23 and 24 of the mLIF 
sequence based on SignalP database. 
Therefore, it encoded a supposed 180 amino-
acid mature mLIF of 19.9 kDa with a pI of 9.2.  
 
The results revealed that full mLIF amino acid 
sequences showed 75-85 % identities to those 
from Rattus norvegicus, Bos taurus, Homo 
sapiens, Pteropus alecto, Sorex araneus, 
Macaca mulatta (Figure 1A). The phylogenic tree 
of LIF was established according to the amino 
acid sequence of selected LIF from different 
species (Figure 1B), mLIF was initially clustered 
with Rattus norvegicus LIF. 
 
Rare codons  
 
Rare codons in mLIF sequence were searched in 
Rare Codons Calculator (Figure 2A). There were 
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four rare Pro codons at positions 13, 62, 115 and 
157, three rare Ile codons at positions 23, 128 
and 182, two rare Arg codons at positions 132 
and 167 and one rare Leu codon at position 68 in 
the 570 bp mLIF sequence encoding mature 
mLIF. All 10 rare codons in the mLIF sequence 
were replaced by the preferred codons of E. coli, 
generating the mLIFm sequence (Figure 2B).  
 
 
Figure 1: (A) Alignment of amino acid sequences of LIF for mouse and other species. (B) A phylogenetic tree of 
LIF from different species. It was constructed by Phylip-3.69 program. Numbers represent the values given by 
bootstrap analysis. The species names (in parenthesis) of different LIF are shown on the right. 
 
Figure 2: (A) Rare codons in mLIF sequence (B) Rare codon replaced by preferred codons of E. coli in mLIFm 
sequence. The codons marked in red were the modified rare codons 
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Figure 3: (A) SDS-PAGE analysis of expressed and 
purified rmLIF and rmLIFm protein. Lane M, protein 
molecular weight standards; lane 1, uninduced E. coli; 
lane 2, supernatant of rmLIFm; Lane 3, supernatant of 
rmLIF; lanes 4 and 5, the purified rmLIFm; lanes 6 and 
7, the purified rmLIFm after dialysis. (B)Detection of 
protein expression by western blot. Lane 1, the 
purified rmLIFm protein by Ni–NTA affinity 
chromatography; lane 2, uninduced E. coli lysate 
 
The best optimized conditions for expression of 
recombinant protein in soluble form was acquired 
by induction with 0.5 mM IPTG at 18 °C for 16 h. 
Induced culture was harvested which produced 
3.2 g wet weight cells per 500 ml culture. After 
sonication, the supernatant and pellet was 
analyzed by SDS-PAGE (Figure 3A). Both rmLIF 
and rmLIFm showed an apparent band about 
23.55 kDa after induction. After reforming the 
rare codons soluble form (Lane 2, Figure 3A) 
accounts for 35.2 % of total expressed soluble 
rmLIFm in the supernatant of the lysate, 
compared with rmLIF accounted for only 29.1 % 
(Lane 3, Figure 3A). 
 
The supernatant was purified by Ni-NTA affinity 
chromatography. The results showed that the 
protein had been purified with a purification yield 
of 97.5 % according to its migration (Figure 3A). 
The presence of the protein was confirmed with 
anti-His-tag by Western blot (Figure 3B). As 
noted in the present study, a tag-based protein 
purification method was used. The expression 
level of rmLIFm approximated 141 mg/L. Its 
production increased by one third when 
compared with the original rmLIF. 
 
Mass spectra  
 
Figure 4 shows the mass spectrum the trypsin 
digest of the purified rmLIFm. There were four 
major peptides at 1031.57, 1539.82, 1412.01 
and 2229.10 m/z. The strongest peak was 
appeared on 1412.01, which fit to the predict 
molecular weight of HGAGSPLPITPVNATCAI 
peptide fragment. This result was a further 




Figure 4: MALDI-TOF mass spectrum of purified rmLIFm. The purified rmLIFm was determined on SDS-PAGE gel 
and the rmLIFm in a piece of gel was subjected to in-gel digestion with trypsin. The resulting polypeptide was 
analyzed by MALDI-TOF MS 
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Biological activity  
 
The biological activity of rmLIFm could be 
identified on account of its ability to maintain the 
proliferation potential of pluripotent stem cell after 
numerous passages while retaining their 
pluripotency [12,14]. The results in Figure 5A 
indicated that the group supplied with rmLIFm 
expressing the ESCs markers were similar to the 
positive control group. Importantly, no ESCs 
markers expression was detected in MEF which 
were used as a negative control. In addition, after 
10 passages in culture, compared with the 
mESC colonies not treated with rmLIFm, the 
group treated with rmLIFm fusion protein 
maintained cell structure integrity, the shape is 
circular with an intact nucleus, mESC colonies 
not treated with rmLIFm were varied and most 
presented nested or island shapes (Figure 5B). 
The mESC colonies added to rmLIFm fusion 
protein were further detected 
by  immunofluorescence staining with nuclear 
markers, along with the stage-specific embryonic 
antigen-1 (SSEA-1), and the results showed that 
the four stem cell factors were all induced by 




Figure 5: (A) Realtime-PCR analysis of the pluripotent markers, Nanog, Oct-4, and Sox-2 relative expression 
over GAPDH in mESCs after 5 passages in culture with commercial mLIF, rmLIFm supplemented media; (B) 
Morphology of mESCs colonies (phase contrast) after 10 passages in medium containing 10 ng/mL rmLIFm (left) 
and not treated with rmLIFm (right); (C) Immunofluorescence imaging of stem cell markers Sox-2 (upper left), 
Oct-4 (upper right), Nanog (below left) and SSEA-1 (lower right), respectively. DAPI was used to counterstain cell 
nucleus, Scale bar, 10 μm 
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To date, a large number of expression systems 
were used to express LIFs. Among them, 
majority is hLIF. Low expression yields, misfolds 
and aggregates, however, prevented laboratories 
from applying LIF. 
 
Sequence analysis of mLIF demonstrated that 
there were 10 rare codons in the 570 bp mLIF 
sequence encoding mature mLIF which would 
lower mLIF protein expression levels. In order to 
overcome the problem of rare codons, we 
optimized it from rare codons to E. coli preferred 
ones.Although E. coli is a helpful host for 
expression of heterologous protein, differences in 
codon usage preference between the original 
organism and E. coli could lead to significant 
reduction in expression level [15]. Similar reports 
showed that replacing rare codon increased the 
expression of beta-G glucosidase by 2- and 3.6-
fold [16]. 
 
A major drawback would be that expression of 
heterologous protein in large quantities in E. coli 
often leads to the formation of inclusion bodies 
[17]. Most of the protein were expressed as 
inclusion bodies at 37 ºC. Along with the form of 
inclusion bodies, there are usually complicated 
and unstable refolding procedures which tend to 
bring about low purification yields [18]. To solve 
this problem, we used the optimal induction 
temperature at 18 ºC, the protein was expressed 
mostly as a soluble form. Lower temperature 
makes it easy to form correct protein folding and 
increase protein solubility [19]. On the other 
hand, mLIFm protein contains three disulfide 
bonds formed by six conserved cysteine residues 
[20]. The Rosetta-gami host strain also carried 
the trxB/gor mutations, which could enhance 
disulfide bond formation. Our study also 
demonstrates that the rmLIFm produced had 
correct folding structure. Furthermore, this 
approach took advantage of the small flexible N-
terminal six His affinity tag system for easy 
purification of fusion protein tagged with a 
polyhistidine sequence. Compared with other 
tags, Glutathione S-transferase (GST) and 
thioredoxin (Trx) which can improve solubility 
and yields, it is small enough to not alter 
functional properties of the tagged proteins and 
maintain biological activity of recombinant 
proteins. 
 
As noted in the present study, we used an affinity 
tag-based purification method to make the 
purification easy. Meanwhile, soluble mLIFm 
protein can easily be obtained and its expression 
level rose to approximately 141 mg/L per 1 L 
medium. In contrast with previous study, the yield 
of rmLIFm protein was higher. 1.3 mg hLIF were 
got from 3.8 g cells (wet weight) of 1 L culture by 
Jung et al [21]. About 30 mg untagged hLIF per 
1L EnBse Flo culture was achieved after one-
step eXactTM affinity chromatographic purification 
by Imaizumi et al [10]. Furthermore, Western blot 
and mass spectrometry were used to identify 
rmLIFm fusion protein. 
 
As demonstrated, purified rmLIFm was helpful in 
maintaining the multiplication potential of mESCs 
throughout numerous passages. These results 
indicated that mESCs with rmLIFm protein 
treatment showed common multipotent markers. 
The undifferentiation potential of pluripotent stem 
cells can be maintained after long-term culture 
with rmLIFm. More importantly, His-tag portion 
showed no significant effect on the bioactivity of 
rmLIFm. Production is cost-effective in bacteria 
culture. In addition, the protein purification 
methodology is simple, practical and cost-





By adopting optimizing codons, using small 
molecular weight His tags and prokaryotic host 
Rosetta-gami, a straightforward and effective 
method to produce large amounts of soluble 
mLIFm is presented. The strategy not only 
provides an effective and fast way to produce 
rmLIFm which is not only helpful in maintaining 
the multiplication potential of mESCs and 
retaining their pluripotency, but also might be 
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